Unknown

Dataset Information

0

Innate immune activation by tissue injury and cell death in the setting of hematopoietic stem cell transplantation.


ABSTRACT: Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) with donor lymphocyte infusion is the mainstay of treatment for many types of hematological malignancies, but the therapeutic effect and prevention of relapse is complicated by donor T-cell recognition and attack of host tissue in a process known as graft-versus-host disease (GvHD). Cytotoxic myeloablative conditioning regimens used prior to Allo-HSCT result in the release of endogenous innate immune activators that are increasingly recognized for their role in creating a pro-inflammatory milieu. This increased inflammatory state promotes allogeneic T-cell activation and the induction and perpetuation of GvHD. Here, we review the processes of cellular response to injury and cell death that are relevant following Allo-HSCT and present the current evidence for a causative role of a variety of endogenous innate immune activators in the mediation of sterile inflammation following Allo-HSCT. Finally, we discuss the potential therapeutic strategies that target the endogenous pathways of innate immune activation to decrease the incidence and severity of GvHD following Allo-HSCT.

SUBMITTER: Brennan TV 

PROVIDER: S-EPMC4360715 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Innate immune activation by tissue injury and cell death in the setting of hematopoietic stem cell transplantation.

Brennan Todd V TV   Rendell Victoria R VR   Yang Yiping Y  

Frontiers in immunology 20150316


Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) with donor lymphocyte infusion is the mainstay of treatment for many types of hematological malignancies, but the therapeutic effect and prevention of relapse is complicated by donor T-cell recognition and attack of host tissue in a process known as graft-versus-host disease (GvHD). Cytotoxic myeloablative conditioning regimens used prior to Allo-HSCT result in the release of endogenous innate immune activators that are increasingly  ...[more]

Similar Datasets

| S-EPMC4092101 | biostudies-literature
| S-EPMC6163303 | biostudies-literature
| S-EPMC4424169 | biostudies-other
| S-EPMC6892976 | biostudies-literature
| S-EPMC4801796 | biostudies-other
2018-10-24 | PXD002437 | Pride
| S-EPMC6790281 | biostudies-literature
| S-EPMC4955710 | biostudies-literature
| S-EPMC9221514 | biostudies-literature
| S-EPMC6865355 | biostudies-literature